Browse by author
Lookup NU author(s): Dr David Mantle,
Emeritus Professor Elaine Perry
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Various active compounds derived primarily from Oriental and European medicinal plants, including Ginkgo biloba, Panax ginseng, Nicotiana tobaccum, Huperzia serrata, Galanthus nivalis and Salvia officinalis, have been assessed for their efficacy in dementia, primarily in Alzheimer's disease. These plants may be used individually or, particularly in traditional Chinese or Ayurvedic formulations, in combination. The mechanisms of action of medicinal plant extracts in Alzheimer's disease have yet to be fully determined, but are thought to involve anticholinesterase, anti-inflammatory, antioxidant and estrogenic activity, and cholinergic receptor activation. Robust clinical trial data are currently scarce. However, those that are available confirm the effectiveness of G. biloba in delaying deterioration or inducing symptomatic improvement in patients with Alzheimer's disease. In addition, the extract does not appear to be associated with adverse or toxic effects. The active component of G. nivalis, the selective acetylcholinesterase inhibitory alkaloid galantamine (galanthamine), is currently commercially available in Austria and is preregistrational in a number of other countries for the symptomatic treatment of mild/moderate Alzheimer's disease. Currently available data indicate galantamine to be well tolerated in the long term, with a relative lack of toxicity at clinically effective dosages. Future development of effective novel therapeutic strategies for dementia may benefit from the combination of conventional Western medical science and traditional Oriental medical practices.
Author(s): Mantle D, Pickering AT, Perry EK
Publication type: Review
Publication status: Published
Journal: CNS Drugs
Print publication date: 01/01/2000
ISSN (print): 1172-7047
ISSN (electronic): 1179-1934